Physician
Psychiatry
Dr. John K. Hsiao, MD
|
|
Give Review
John Hsiao is an expert in the field of Psychiatry. He researched medicine at University of Maryland School of Medicine. University of Maryland School of Medicine is ranked 37/52 in Research/PrimaryCare. Doctor John K. Hsiao, MD is also a published physician. He has 51 publication published. The most recent publication is: Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD.
- Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
- Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.
- What CATIE found: results from the schizophrenia trial.
- Interpreting the results of the CATIE study.
- Disparate Biochemical Actions of Electroconvulsive Therapy and Antidepressant Drugs.
- ECT and Neurological Disorders.
- The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls.
- A study of the TRH test in a family with psychiatric illness: a reflection on the TRH test as a state-trait marker.
- Is there paradoxical growth hormone response to thyrotropin-releasing hormone in depression?
- Diagnosing diagnoses. Receiver operating characteristic methods and psychiatry.
- Effects of renal clearance on plasma concentrations of homovanillic acid. Methodologic cautions.
- The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects.
- The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects.
- Monoamine neurotransmitter interactions and the prediction of antidepressant response.
- Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment.
- Munchausen syndrome, depression, and the dexamethasone suppression test.
- ECT in a depressed patient after craniotomy.
- Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy.
- Abnormal neuroendocrine responsivity to acute i.v. clomipramine challenge in depressed patients.
- The effects of intravenous clomipramine on neurohormones in normal subjects.
- Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial.
- Predictors of clozapine response in schizophrenia.
- Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.
- Clozapine treatment of schizophrenia.
- Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
- Measuring outcome priorities and preferences in people with schizophrenia.
- Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
- Use of Antipsychotics Pre- and Post-Dissemination of CATIE Data.
- Clinical response to clozapine in patients with schizophrenia.
- Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
- Antipsychotics: Past and Future: National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998.
- National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
- Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
- Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schi...
- Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
- Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
- The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
- Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.
- Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
- Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
- Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
- Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
- Effectiveness of atypical antipsychotic drugs in patients with Alzheimer''s disease.
- Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsych...
- Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic tr...
- Barriers to employment for people with schizophrenia.
- Results of phase 3 of the CATIE schizophrenia trial.
- Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
- Clinical symptom responses to atypical antipsychotic medications in Alzheimer''s disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Schools
University of Maryland At Baltimore Professional Schools
Clin Center Nih
North Carolina Memorial Hospital
Nimh
Doctors Specialties
- Nuclear Medicine
- Psychiatry
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Select
- Blue Card PPO
- Blue Preferred PPO
- Cigna
- Commercial Insurance Company
- Humana
- Kaiser Permanente
- Medicaid
- Medicare MCR
- Tricare
- United Healthcare
Education
-
National Institutes of Health Clinical Center -
University of North Carolina Hospitals -
University of Maryland -
University of Maryland School of Medicine
Hospital
-
Holy Cross Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1346348018 |
| Last Name Of The Provider | HSIAO |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Mehran Bajoghli, MD |
|
|
Dr. Catherine Ostell, MD |
|
|
Dr. Naveena Hemanth, MD |
|
|
Dr. Nadia W. Krupnikova, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hemanjani Gonchigar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abby Z. Wellman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas M. Mould, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vladmir Demidov, MD |
|
|
Dr. Robert L. Dupont Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Won S. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew V. Rudorfer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vijay M. Varma, MD
This Doctor is OpenDoctor Recommended.
|